Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. Our digital biomarker detection technology, Simoa, has the potential to transform healthcare by giving researchers the ability to more closely examine the continuum from health to disease. With up to 1,000X greater sensitivity over traditional ELISA, Simoa is designed to enable earlier detection of neurological disease, better prognoses and enhanced treatment methods to improve quality of life and longevity. The company was established in 2007 and is located in Billerica, MA, USA.
InSysBio is a private research organization focused on application of system-pharmacology modelling to different stages of drug research and development.
Our approach enables us to reconstruct the effects of taking medication in terms of clinically measured biomarkers and end-points, predict the efficacy of a drug in humans on the basis of data obtained in animals, search for optimal combinational therapies, describe biotechnological processes, and more.
Cortexyme is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases. Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer’s disease. Cortexyme is targeting a specific, infectious pathogen found in the brain of Alzheimer’s patients that causes neurodegeneration and other pathology in animal models. Additional programs are progressing in preclinical development.